和铂医药-B子公司与辉瑞签非独家授权协议

财中社
Nov 19

  11月19日,和铂医药-B(02142)发布公告,本公司全资子公司诺纳生物(苏州)有限公司已与辉瑞订立非独家授权协议,旨在推进针对多种潜在疾病适应症的临床前抗体发现工作。

  根据协议条款,辉瑞将获得诺纳生物专有HCAb平台的全球使用权,以开发全人源仅重链抗体。诺纳生物将获得首付款,并有权获得监管、临床及商业里程碑付款。

  此外,诺纳生物可与辉瑞合作,利用诺纳生物的HCAb平台、先进的B细胞筛选技术及综合服务开展抗体发现、开发及工程。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10